| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
|
| | Glabrescione B Basic information |
| Product Name: | Glabrescione B | | Synonyms: | Glabrescione B;Glabrescione B
(GlaB);3-[3,4-bis-(3-methyl-but-2-enyloxy)-phenyl]-5,7-dimethoxy-chromen-4-one;GlaB;4H-1-Benzopyran-4-one, 3-[3,4-bis[(3-methyl-2-buten-1-yl)oxy]phenyl]-5,7-dimethoxy- | | CAS: | 65893-94-9 | | MF: | C27H30O6 | | MW: | 450.52 | | EINECS: | | | Product Categories: | | | Mol File: | 65893-94-9.mol |  |
| | Glabrescione B Chemical Properties |
| Boiling point | 608.0±55.0 °C(Predicted) | | density | 1.142±0.06 g/cm3(Predicted) | | form | Solid | | color | White to off-white |
| | Glabrescione B Usage And Synthesis |
| Uses | Glabrescione B is the first compound that binds the Hedgehog (Hh) modulator Gli1. Glabrescione B impairs its activity by interfering with Gli1-DNA interaction. Glabrescione B inhibits the growth of Hedgehog-dependent tumor cells, the self-renewal ability, and clonogenicity of tumor-derived stem cells[1][2]. | | Definition | ChEBI: Glabrescione B is a methoxyisoflavone. | | in vivo | | Animal Model: | Female NOD/SCID mice (ASZ001 BCC allografts)[2] | | Dosage: | 100 μmol/kg | | Administration: | I.p.; every second day for 18 days | | Result: | A significant reduction of tumor growth as well as Gli1 mRNA levels was observed.
|
| | References | [1] Ingallina C, et al. Polymeric glabrescione B nanocapsules for passive targeting of Hedgehog-dependent tumor therapy in vitro. Nanomedicine (Lond). 2017;12(7):711-728. DOI:10.2217/nnm-2016-0388
[2] Infante P, et al. Gli1/DNA interaction is a druggable target for Hedgehog-dependent tumors. EMBO J. 2015;34(2):200-217. DOI:10.15252/embj.201489213 |
| | Glabrescione B Preparation Products And Raw materials |
|